-
Two novel missense mutations in EPOR gene causes erythrocytosis in two unrelated patients.
-
Here, we present two crystal structures of the human JAK2 FERM and SH2 domains bound to Leptin receptor (LEPR) and Erythropoietin receptor (EPOR), which identify a novel dimeric conformation for JAK2.
-
EpoR role in the proliferation and survival of non-small cell lung cancer cells
-
These results highlight the high intrinsic specificity of transmembrane domain interactions, demonstrate that a single methyl group can dictate specificity, and define the minimal chemical difference that can modulate the specificity of transmembrane domain interactions and the activity of transmembrane proteins.
-
Study reports for the first evidence that EPOR modulates breast cancer cell morphology changes upon tamoxifen treatment, which result in increased formation of cell protrusions and subsequent cell death and, proposes sustained AKT phosphorylation in EPOR-overexpressing cells as a mechanism that can lead to EPOR-induced tamoxifen resistance.
-
Authors retrospectively investigated whether TFR2 isoforms and EPOR are differentially expressed in MDS patients and whether the expression is associated with patients' clinical outcomes.
-
High EPOR expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.
-
EPO-mediated EPOR signaling reduced the viability of myeloma cell lines and of malignant primary plasma cells in vitro
-
this study shows that EPO could directly promote tumor progression via EPO receptor-expressing macrophages
-
No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA. CONCLUSION: Thus, in contradiction to animal studies, Epo treatment within a physiological relevant range in humans does not exert direct effects in a subcutaneous WAT.
-
Our results suggest that EPO/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis
-
These results suggest that both EpoR-positive and EpoR-negative cancer cells could be regulated by exogenous Epo. However, an increased response to erythropoietin was observed in the EpoR-positive cells. Thus, erythropoietin increases the risk of tumor progression in colon cancer and should not be used to treat anemia in this type of cancer.
-
Overexpression of EPOR is associated with clear cell renal cell carcinoma.
-
HIF-1alpha and EPO-R may be an indicator of the aggressiveness of invasive breast cancers
-
In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to overall survival in hepatocellular carcinoma.
-
These results identify EPOR as the secondbona fidehydroxylation-dependent substrate of VHL that potentially influences oxygen homeostasis and contributes to the complex genotype-phenotype correlation in VHL disease.
-
We report for a first time that functional EpoR is expressed in human rhabdomyosarcoma cell lines as well as by primary tumors from RMS patients.
-
erythrocyte lineage enforces exclusivity through upregulation of EKLF and its lineage-specific cytokine receptor (EpoR) while inhibiting both FLI-1 and the receptor TpoR (also known as MPL) for the opposing megakaryocyte lineage
-
A new point mutation in EPOR induces a short deletion in congenital erythrocytosis.
-
Data show that erythropoietin receptor antagonist EMP9 suppressed hemoglobin synthesis in xenografts of HeLa cells.
